US Patent Issued to Juno Therapeutics on July 21 for "Anti-idiotypic antibodies to BCMA-targeted binding domains and related compositions and methods" (Washington Inventors)

ALEXANDRIA, Va., July 21 -- United States Patent no. 12,686,728, issued on July 21, was assigned to Juno Therapeutics Inc. (Seattle).

"Anti-idiotypic antibodies to BCMA-targeted binding domains and related compositions and methods" was invented by Collin Hauskins (Seattle) and Kimberly Harrington (Seattle).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are anti-idiotype antibodies that specifically recognize anti-BCMA antibody moieties, in particular, anti-BC-MA antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of antiidiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant...